Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD).

This study describes general synthesis aspects of fragments for FBDD, as illustrated by the dihydroisoquinolones 1-3. Previous Rh(III) methodology is extended to incorporate amines, heteroatoms (N and S), and substituents (halogen, ester) as potential binding groups and/or synthetic growth points for fragment-to-lead elaboration.

[1]  Ajay,et al.  The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.

[2]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[3]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[4]  Brian Dymock,et al.  Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets , 2004, J. Chem. Inf. Model..

[5]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[6]  Mike Cherry,et al.  Introduction to Fragment‐Based Drug Discovery , 2008 .

[7]  Zhihui Zhang,et al.  N‐Amidation by Copper‐Mediated Cross‐Coupling of Organostannanes or Boronic Acids with O‐Acetyl Hydroxamic Acids. , 2008 .

[8]  Niklas Blomberg,et al.  Design of compound libraries for fragment screening , 2009, J. Comput. Aided Mol. Des..

[9]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[10]  R. D. Farrant,et al.  NMR quantification using an artificial signal , 2010, Magnetic resonance in chemistry : MRC.

[11]  Nicolas Guimond,et al.  Rhodium(III)-Catalyzed Isoquinolone Synthesis: The N-O Bond as a Handle for C-N Bond Formation and Catalyst Turnover. , 2010 .

[12]  G. Lushington,et al.  Design, synthesis, and in vitro evaluation of potential West Nile virus protease inhibitors based on the 1-oxo-1,2,3,4-tetrahydroisoquinoline and 1-oxo-1,2-dihydroisoquinoline scaffolds. , 2010, Journal of combinatorial chemistry.

[13]  James E. J. Mills,et al.  Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics , 2011, J. Comput. Aided Mol. Des..

[14]  A. Leach,et al.  Molecular complexity and fragment-based drug discovery: ten years on. , 2011, Current opinion in chemical biology.

[15]  Frank Glorius,et al.  Rh(III)-catalyzed directed C-H olefination using an oxidizing directing group: mild, efficient, and versatile. , 2011, Journal of the American Chemical Society.

[16]  Nicolas Guimond,et al.  Rhodium(III)-catalyzed heterocycle synthesis using an internal oxidant: improved reactivity and mechanistic studies. , 2011, Journal of the American Chemical Society.

[17]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[18]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[19]  Thomas R. Ward,et al.  Biotinylated Rh(III) Complexes in Engineered Streptavidin for Accelerated Asymmetric C–H Activation , 2012, Science.

[20]  Channa K. Hattotuwagama,et al.  Lead-oriented synthesis: a new opportunity for synthetic chemistry. , 2012, Angewandte Chemie.

[21]  N. Cramer,et al.  Chiral Cyclopentadienyl Ligands as Stereocontrolling Element in Asymmetric C–H Functionalization , 2012, Science.

[22]  Daniel A Erlanson,et al.  Learning from our mistakes: the 'unknown knowns' in fragment screening. , 2013, Bioorganic & medicinal chemistry letters.

[23]  T. Hwang,et al.  Rh(III)-catalyzed C-H activation and double directing group strategy for the regioselective synthesis of naphthyridinones. , 2013, Journal of the American Chemical Society.

[24]  Harren Jhoti,et al.  The 'rule of three' for fragment-based drug discovery: where are we now? , 2013, Nature Reviews Drug Discovery.

[25]  Nathan Brown,et al.  Fragment-based hit identification: thinking in 3D. , 2013, Drug discovery today.

[26]  Frederik J. R. Rombouts,et al.  Complementary regioselectivity in Rh(III)-catalyzed insertions of potassium vinyltrifluoroborate via C-H activation: preparation and use of 4-trifluoroboratotetrahydroisoquinolones. , 2013, Organic letters.

[27]  N. Cramer,et al.  Asymmetric synthesis of isoindolones by chiral cyclopentadienyl-rhodium(III)-catalyzed C-H functionalizations. , 2014, Angewandte Chemie.

[28]  Edward R Zartler,et al.  Fragonomics: the -omics with real impact. , 2014, ACS medicinal chemistry letters.

[29]  T. Magee.  Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening. , 2015, Bioorganic & medicinal chemistry letters.

[30]  Rhodium‐Catalyzed C—H Functionalization‐Based Approach to Eight‐Membered Lactams. , 2015 .

[31]  Nicola J. Webb,et al.  Rhodium(III)-Catalyzed C—H Activation/Annulation with Vinyl Esters as an Acetylene Equivalent. , 2015 .

[32]  T. Rovis,et al.  Ligand design for Rh(iii)-catalyzed C–H activation: an unsymmetrical cyclopentadienyl group enables a regioselective synthesis of dihydroisoquinolones , 2014, Chemical Science.

[33]  Anders Friberg,et al.  Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design. , 2015, Journal of medicinal chemistry.

[34]  Christopher W Murray,et al.  Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD). , 2016, Angewandte Chemie.

[35]  T. Rovis,et al.  Correction: Ligand design for Rh(iii)-catalyzed C–H activation: an unsymmetrical cyclopentadienyl group enables a regioselective synthesis of dihydroisoquinolones , 2016, Chemical science.